Paroxysmal atrial fibrillation
Conditions
Interventions
None listed
Sponsors
Cardiology, National defense medical college
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (a) Hyperuricemia (serum urinaric acid level is over 7.0 mg/dl) (b) The patient with apparent attakck of paroxysmal atrial fibrillation (c) The patient aged 20 and over in the time of consent acquisition (d) The document consent by a free intention was obtained. (e) An outpatient and an inpatient
Exclusion criteria
Exclusion criteria: (a) persistent and permanent AF (b) The patient who was new-prescribed in an ACE inhibitor or ARB within six months recently. A patient who had the quantity of an ACE inhibitor or ARB increased within six months. (c) The patient who has mitral stenosis more than the degree of moderate class (d) The patient who received catheter ablation during less than three months or research period. (e) The patient already medicated with allopurinol. (f) A patient with the past of the hypersensitivity to the medicine (g)The patient who has liver disease (AST or ALT >100U) (h)The patient who has a severe renal failure (BUN >30mg/dL, Serum creatinin >2.5mg/dL) (i) The patient under administration of azathioprine, vidarabine and didanosine (contraindications) (j) A woman under pregnancy or with the possibility of pregnancy (k) The woman under breast-feeding (l) The patient who received medication of other trial drugs within three months before the medication (m) In addition, the patient who judged that a chief (assignment) researcher was unsuitable as a subject
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of incidence of atrial fibrillation Shortning of duration of atrial fibrillation | — |
Countries
Japan
Outcome results
None listed